RxFinder.ai

Adalimumab-Adaz

Adalimumab, HYRIMOZ

Tumor Necrosis Factor Blocker

NADAC/unit $1593.3179
No Shortage Tier 1: 1.2% PA Req: 16.4%

Adalimumab-Adaz suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.

vs. brand Adalimumab: Generic saves up to -15833% per unit

Active Shortages

2026-01-13 Equivalent Sandoz format is available., Sandoz Inc.
2026-01-13 Equivalent Sandoz format is available., Sandoz Inc.
2026-01-13 Equivalent Sandoz format is available., Sandoz Inc.
2026-01-13 Equivalent Sandoz format is available., Sandoz Inc.
2026-01-13 Equivalent Sandoz format is available., Sandoz Inc.

Explore in the Ecosystem

rxsaver.aiCompare prices for Adalimumab-Adazdrfinder.aiFind doctors who prescribe Adalimumab-Adazrxbenefits.aiEmployer cost impact analysisclinicalrx.aiClinical profile: Adalimumab-Adaz

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.